Here's What Analysts Think of NTRA.

This afternoon we watched Natera drop -2.3% to a price of $51.77 per share. The mid-cap Medical Specialities company is now trading -31.37% below its average target price of $75.43. Analysts have set target prices ranging from $29.0 to $117.0 per share for Natera, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 5.7%, and a short ratio of 3.48. Since 3.38% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.7% of Natera's shares being owned by this investor type.

Institutions Invested in Natera

Date Reported Holder Percentage Shares Value
2022-12-31 Vanguard Group, Inc. (The) 9% 9,945,514 $514,829,526
2022-12-31 Fred Alger Management, LLC 8% 8,972,823 $464,478,177
2022-12-31 JP Morgan Chase & Company 5% 6,202,712 $321,083,382
2022-12-31 Blackrock Inc. 5% 5,566,939 $288,172,593
2022-12-31 Samlyn Capital, LLC 4% 4,390,372 $227,267,603
2022-12-31 State Street Corporation 3% 3,572,262 $184,918,140
2022-12-31 Sofinnova Investments, Inc. 3% 3,100,560 $160,500,486
2022-12-31 Citadel Advisors Llc 3% 3,048,948 $157,828,791
2022-12-31 Norges Bank Investment Management 2% 2,780,428 $143,928,853
2022-12-31 Eversept Partners, LP 2% 2,685,959 $139,038,665

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Natera.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.